61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
Leipzig,
25.–28.03.2020
Kongresspräsident: Prof. Dr. med. Gernot Rohde
P62
Kreuter, M;
Bonella, F;
Blank, N;
Siegert, E;
Henes, J;
Worm, M;
Sunderkoetter, C;
Schmalzing, M;
Kreuter, A;
Guenther, C;
Susok, L;
Zeidler, G;
Koetter, I;
Mueller-Ladner, U;
Krieg, T;
Juche, A;
Schmeiser, T;
Riemekasten, G;
Aberer, E;
Gaebelein-Wissing, N;
Distler, JHW;
Sárdy, M;
Pfeiffer, C;
Kuhr, K;
Lorenz, HM;
Moinzadeh, P;
Hunzelmann, N:
Does anti-acid treatment influence disease progression in SSc-ILD? Data form the German SSc-network
P63
Kreuter, M;
Bonella, F;
Blank, N;
Siegert, E;
Henes, J;
Worm, M;
Sunderkoetter, C;
Schmalzing, M;
Kreuter, A;
Guenther, C;
Susok, L;
Zeidler, G;
Koetter, I;
Mueller-Ladner, U;
Krieg, T;
Juche, A;
Schmeiser, T;
Riemekasten, G;
Aberer, E;
Gaebelein-Wissing, N;
Distler, JHW;
Sárdy, M;
Pfeiffer, C;
Kuhr, K;
Lorenz, HM;
Moinzadeh, P;
Hunzelmann, N:
Long term outcomes of immunmodulatory drugs in SSc-ILD – data rom the German SSc network
P151
Kreuter, M;
Highland, KB;
Kuwana, M;
Azuma, A;
Maher, T;
Mayes, MD;
Raghu, G;
Girard, M;
Kohlbrenner, V;
Clerisme-Beaty, E;
Alves, M;
Distler, O:
Dose adjustments in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)*
P154
Kreuter, M;
Highland, KB;
Azuma, A;
Kuwana, M;
Maher, TM;
Mayes, MD;
Raghu, G;
Girard, M;
Alves, M;
Gahlemann, M;
Distler, O:
Changes in FVC in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)*
P155
Prasse, A;
Maher, TM;
Distler, O;
Azuma, A;
Highland, KB;
Kuwana, M;
Mayes, MD;
Wachtlin, D;
Alves, M;
Gahlemann, M;
Stowasser, S;
Raghu, G:
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS Trial*
P156
Prasse, A;
Distler, O;
Highland, KB;
Gahlemann, M;
Azuma, A;
Mayes, MD;
Raghu, G;
Sauter, W;
Girard, M;
Alves, M;
Clerisme-Beaty, E;
Kuwana, M;
Maher, TM:
Nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): the SENSCIS trial*
P157
Wiewrodt, R;
Raghu, G;
Distler, O;
Azuma, A;
Highland, KB;
Kuwana, M;
Mayes, MD;
Wachtlin, D;
Stowasser, S;
Alves, M;
Gahlemann, M;
Maher, TM:
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial*
P158
Wiewrodt, R;
Vonk, M;
Distler, O;
Furst, D;
Hachulla, E;
Johnson, S;
Assassi, S;
Meng, L;
Quaresma, M;
Alves, M;
Clerisme-Beaty, E;
Wuyts, WA:
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use*
P159
Bonella, F;
Matteson, E;
Kelly, C;
Distler, JHW;
Hoffmann-Vold, A;
Seibold, JR;
Mittoo, S;
Distler, O;
Goeldner, RG;
Schlenker-Herceg, R;
Stowasser, S;
Quaresma, M;
Flaherty, KR:
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Instititial Lung Diseases: Subgroup with Autoimmune Diseases*
P334
Nagel, C;
Nasereddin, M;
Benjamin, N;
Egenlauf, B;
Harutyunova, S;
Eichstaedt, C;
Xanthouli, P;
Mayer, E;
Grünig, E;
Guth, S:
Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension (CTEPH) as early follow-up treatment after pulmonary endarterectomy (PEA) – a prospective cohort study
P555
Rosenkranz, S;
Channick, R;
Chin, K;
Jenner, B;
Gaine, S;
Galie, N;
Ghofrani, HA;
Hoeper, MM;
McLaughlin, V;
Preiss, R;
Rubin, L;
Simonneau, G;
Sitbon, O;
Tapson, V;
Lang, I:
Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
P535
Gaine, S;
Sitbon, O;
Channick, R;
Chin, K;
Di Scala, L;
Galie, N;
Hoeper, MM;
McLaughlin, V;
Preiss, R;
Rubin, L;
Simonneau, G;
Tapson, V;
Ghofrani, HA;
Lang, I:
The impact of time from diagnosis at baseline on long-term outcome in the GRIPHON Study: Selexipag in pulmonary arterial hypertension (PAH)
